93 related articles for article (PubMed ID: 11452245)
1. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
2. Potential interaction between clarithromycin and warfarin.
Recker MW; Kier KL
Ann Pharmacother; 1997 Sep; 31(9):996-8. PubMed ID: 9296238
[TBL] [Abstract][Full Text] [Related]
3. Protein binding: what does it mean?
Scheife RT
DICP; 1989; 23(7-8 Suppl):S27-31. PubMed ID: 2669380
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and disposition of clarithromycin in man.
Ferrero JL; Bopp BA; Marsh KC; Quigley SC; Johnson MJ; Anderson DJ; Lamm JE; Tolman KG; Sanders SW; Cavanaugh JH
Drug Metab Dispos; 1990; 18(4):441-6. PubMed ID: 1976065
[TBL] [Abstract][Full Text] [Related]
5. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Peters DH; Clissold SP
Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori.
Hsieh PF; Yang JC; Lin JT; Wang JT
J Formos Med Assoc; 1998 Jul; 97(7):445-52. PubMed ID: 9700240
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of action of beta-lactam antibiotics and mechanisms of non-enzymatic resistance].
Williamson R; Collatz E; Gutmann L
Presse Med; 1986 Dec; 15(46):2282-9. PubMed ID: 2949269
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals.
Womble AY; Giguère S; Lee EA; Vickroy TW
Am J Vet Res; 2006 Oct; 67(10):1681-6. PubMed ID: 17014316
[TBL] [Abstract][Full Text] [Related]
9. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain.
Kanazawa K; Nouda H; Sunagawa M
J Antibiot (Tokyo); 1997 Feb; 50(2):162-8. PubMed ID: 9099227
[TBL] [Abstract][Full Text] [Related]
11. Human P450 metabolism of warfarin.
Kaminsky LS; Zhang ZY
Pharmacol Ther; 1997; 73(1):67-74. PubMed ID: 9014207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic profile of posaconazole.
Li Y; Theuretzbacher U; Clancy CJ; Nguyen MH; Derendorf H
Clin Pharmacokinet; 2010 Jun; 49(6):379-96. PubMed ID: 20481649
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of clarithromycin and its 14-OH metabolite.
Davey PG
J Hosp Infect; 1991 Sep; 19 Suppl A():29-37. PubMed ID: 1684980
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants.
Akiyoshi T; Ito M; Murase S; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2013; 28(5):411-5. PubMed ID: 23514827
[TBL] [Abstract][Full Text] [Related]
16. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.
Hirata K; Suzuki H; Nishizawa T; Tsugawa H; Muraoka H; Saito Y; Matsuzaki J; Hibi T
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S75-9. PubMed ID: 20586871
[TBL] [Abstract][Full Text] [Related]
17. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy.
Oberg KC
Pharmacotherapy; 1998; 18(2):386-91. PubMed ID: 9545160
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin clinical pharmacokinetics.
Fraschini F; Scaglione F; Demartini G
Clin Pharmacokinet; 1993 Sep; 25(3):189-204. PubMed ID: 8222460
[TBL] [Abstract][Full Text] [Related]
19. Plasma terminal half-life.
Toutain PL; Bousquet-Mélou A
J Vet Pharmacol Ther; 2004 Dec; 27(6):427-39. PubMed ID: 15601438
[TBL] [Abstract][Full Text] [Related]
20. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
